Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported strong Q2 2025 financial results, with ARCALYST net product revenue reaching $156.8 million, representing a 52% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $625-640 million from $590-605 million.
Key highlights include net income of $17.8 million compared to a $3.9 million loss in Q2 2024, and a robust cash position of $307.8 million. ARCALYST's commercial success continues with over 3,475 prescribers and approximately 15% penetration of the target 14,000 multiple-recurrence patient population.
The company also announced progress in its pipeline, initiating the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, with Phase 2 data expected in 2H 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.